

Special Issue

Recent Advances in Hematological Malignancies in Children

Message from the Guest Editor

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common hematological malignancies in children. The progress made in their treatment over the past few decades, since the end of the 20th century, has been remarkable. Today, we are able to achieve long-term cures in 85-90% of children with ALL and 60-70% of those with AML, compared to approximately 10% in the 1970s. This advancement has been made possible through improved therapeutic protocols based on risk stratification, advancements in diagnostics, as well as the introduction of stem cell transplantation, immunotherapy, and targeted therapies. The purpose of this Special Issue "Recent Advances in Hematological Malignancies in Children" is to showcase the achievements in the treatment of pediatric ALL and AML in recent decades, with a particular focus on new diagnostic and therapeutic methods that have contributed to the improved outcomes in these malignancies. This Special Issue welcomes review articles as well as original research contributions. The deadline for submissions is 30 December 2025. We look forward to your valuable contributions.

Guest Editor

Dr. Radosław Chaber

Department of Pediatrics, Institute of Medical Sciences, University of Rzeszów, Rzeszów, Poland

Deadline for manuscript submissions

30 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/218119

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)